Xeris Biopharma Holdings Inc [NASDAQ: XERS] stock went on an upward path that rose over 15.18% on Thursday, amounting to a one-week price increase of more than 15.18%.
Over the last 12 months, XERS stock rose by 172.30%. The one-year Xeris Biopharma Holdings Inc stock forecast points to a potential upside of 17.44. The average equity rating for XERS stock is currently 1.33, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $794.33 million, with 149.43 million shares outstanding and 141.94 million shares in the current float. Compared to the average trading volume of 3.12M shares, XERS stock reached a trading volume of 5208791 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Xeris Biopharma Holdings Inc [XERS]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for XERS shares is $6.25 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on XERS stock is a recommendation set at 1.33. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Piper Sandler have made an estimate for Xeris Biopharma Holdings Inc shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on November 11, 2024. While these analysts kept the previous recommendation, Oppenheimer raised their target price to Outperform. The new note on the price target was released on March 28, 2024, representing the official price target for Xeris Biopharma Holdings Inc stock. Previously, the target price had yet another raise to $4.50, while Craig Hallum analysts kept a Buy rating on XERS stock.
The Average True Range (ATR) for Xeris Biopharma Holdings Inc is set at 0.32, with the Price to Sales ratio for XERS stock in the period of the last 12 months amounting to 3.91.
XERS Stock Performance Analysis:
Xeris Biopharma Holdings Inc [XERS] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 15.18. With this latest performance, XERS shares gained by 24.94% in over the last four-week period, additionally plugging by 60.25% over the last 6 months – not to mention a rise of 172.30% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for XERS stock in for the last two-week period is set at 63.30, with the RSI for the last a single of trading hit 68.97, and the three-weeks RSI is set at 60.30 for Xeris Biopharma Holdings Inc [XERS]. The present Moving Average for the last 50 days of trading for this stock 4.61, while it was recorded at 4.66 for the last single week of trading, and 3.49 for the last 200 days.
Insight into Xeris Biopharma Holdings Inc Fundamentals:
Xeris Biopharma Holdings Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.19 and a Current Ratio set at 1.67.
Xeris Biopharma Holdings Inc [XERS] Institutonal Ownership Details
The top three institutional holders of XERS stocks are: BLACKROCK INC. with ownership of 10.33 million shares, which is approximately 6.9649%. VANGUARD GROUP INC, holding 7.66 million shares of the stock with an approximate value of $$17.23 million in XERS stocks shares; and VANGUARD GROUP INC, currently with $$11.51 million in XERS stock with ownership which is approximately 3.4469%.
